USFDA concludes inspection at Shilpa Medicare’s Jadcherla facility

09 Sep 2019 Evaluate

US Food and Drug Administration (USFDA) has concluded inspection at Shilpa Medicare’s Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla in the state of Telangana from August 29, 2019 to September 6, 2019.

The inspection concluded with two observations. There were no repeat observations or Data Integrity (DI) related observations.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

325.95 2.15 (0.66%)
16-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2085.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×